Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

PAS kinase drives lipogenesis through SREBP-1 maturation.

Wu X, Romero D, Swiatek WI, Dorweiler I, Kikani CK, Sabic H, Zweifel BS, McKearn J, Blitzer JT, Nickols GA, Rutter J.

Cell Rep. 2014 Jul 10;8(1):242-55. doi: 10.1016/j.celrep.2014.06.006. Epub 2014 Jul 4.

2.

Pharmacology of PF-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain.

Masferrer JL, Zweifel BS, Hardy M, Anderson GD, Dufield D, Cortes-Burgos L, Pufahl RA, Graneto M.

J Pharmacol Exp Ther. 2010 Jul;334(1):294-301. doi: 10.1124/jpet.110.166967. Epub 2010 Apr 8.

PMID:
20378715
3.

Biochemical, cellular, and anti-inflammatory properties of a potent, selective, orally bioavailable benzamide inhibitor of Rho kinase activity.

Rajagopalan LE, Davies MS, Kahn LE, Kornmeier CM, Shimada H, Steiner TA, Zweifel BS, Wendling JM, Payne MA, Loeffler RF, Case BL, Norton MB, Parikh MD, Nemirovskiy OV, Mourey RJ, Masferrer JL, Misko TP, Kolodziej SA.

J Pharmacol Exp Ther. 2010 Jun;333(3):707-16. doi: 10.1124/jpet.110.166033. Epub 2010 Mar 12.

PMID:
20228155
4.

Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor.

Mbalaviele G, Pauley AM, Shaffer AF, Zweifel BS, Mathialagan S, Mnich SJ, Nemirovskiy OV, Carter J, Gierse JK, Wang JL, Vazquez ML, Moore WM, Masferrer JL.

Biochem Pharmacol. 2010 May 15;79(10):1445-54. doi: 10.1016/j.bcp.2010.01.003. Epub 2010 Jan 11.

PMID:
20067770
5.

CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain.

Cortes-Burgos LA, Zweifel BS, Settle SL, Pufahl RA, Anderson GD, Hardy MM, Weir DE, Hu G, Happa FA, Stewart Z, Muthian S, Graneto MJ, Masferrer JL.

Eur J Pharmacol. 2009 Sep 1;617(1-3):59-67. doi: 10.1016/j.ejphar.2009.06.058. Epub 2009 Jul 4.

PMID:
19580807
6.

A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors.

Zweifel BS, Hardy MM, Anderson GD, Dufield DR, Pufahl RA, Masferrer JL.

Eur J Pharmacol. 2008 Apr 14;584(1):166-74. doi: 10.1016/j.ejphar.2008.01.021. Epub 2008 Feb 5.

PMID:
18295198
7.

Enzymologic and pharmacologic profile of loxoprofen sodium and its metabolites.

Noguchi M, Kimoto A, Gierse JK, Walker MC, Zweifel BS, Nozaki K, Sasamata M.

Biol Pharm Bull. 2005 Nov;28(11):2075-9.

8.

Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.

Gierse JK, Zhang Y, Hood WF, Walker MC, Trigg JS, Maziasz TJ, Koboldt CM, Muhammad JL, Zweifel BS, Masferrer JL, Isakson PC, Seibert K.

J Pharmacol Exp Ther. 2005 Mar;312(3):1206-12. Epub 2004 Oct 19.

PMID:
15494548
9.

Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature.

Davis TW, O'Neal JM, Pagel MD, Zweifel BS, Mehta PP, Heuvelman DM, Masferrer JL.

Cancer Res. 2004 Jan 1;64(1):279-85.

10.

Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting.

Davis TW, Zweifel BS, O'Neal JM, Heuvelman DM, Abegg AL, Hendrich TO, Masferrer JL.

J Pharmacol Exp Ther. 2004 Mar;308(3):929-34. Epub 2004 Jan 7.

PMID:
14711936
11.

The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice.

Lanza-Jacoby S, Miller S, Flynn J, Gallatig K, Daskalakis C, Masferrer JL, Zweifel BS, Sembhi H, Russo IH.

Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1486-91.

12.

Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment.

Wilgus TA, Koki AT, Zweifel BS, Kusewitt DF, Rubal PA, Oberyszyn TM.

Mol Carcinog. 2003 Oct;38(2):49-58.

PMID:
14502644
13.

Chemotherapeutic efficacy of topical celecoxib in a murine model of ultraviolet light B-induced skin cancer.

Wilgus TA, Koki AT, Zweifel BS, Rubal PA, Oberyszyn TM.

Mol Carcinog. 2003 Sep;38(1):33-9.

PMID:
12949841
14.

Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.

Zweifel BS, Davis TW, Ornberg RL, Masferrer JL.

Cancer Res. 2002 Nov 15;62(22):6706-11.

15.

Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.

Trifan OC, Durham WF, Salazar VS, Horton J, Levine BD, Zweifel BS, Davis TW, Masferrer JL.

Cancer Res. 2002 Oct 15;62(20):5778-84.

16.

Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo.

Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL.

Cancer Res. 2002 Feb 1;62(3):625-31.

17.

Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.

Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K.

Cancer Res. 2000 Mar 1;60(5):1306-11.

18.

4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2.

Talley JJ, Brown DL, Carter JS, Graneto MJ, Koboldt CM, Masferrer JL, Perkins WE, Rogers RS, Shaffer AF, Zhang YY, Zweifel BS, Seibert K.

J Med Chem. 2000 Mar 9;43(5):775-7. No abstract available.

PMID:
10715145
19.

Inhibitory effects of caffeic acid phenethyl ester on the activity and expression of cyclooxygenase-2 in human oral epithelial cells and in a rat model of inflammation.

Michaluart P, Masferrer JL, Carothers AM, Subbaramaiah K, Zweifel BS, Koboldt C, Mestre JR, Grunberger D, Sacks PG, Tanabe T, Dannenberg AJ.

Cancer Res. 1999 May 15;59(10):2347-52.

20.

Pharmacological analysis of cyclooxygenase-1 in inflammation.

Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, Talley JJ, Masferrer JL, Seibert K, Isakson PC.

Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13313-8.

21.

Regulation of prostaglandin biosynthesis in vivo by glutathione.

Margalit A, Hauser SD, Zweifel BS, Anderson MA, Isakson PC.

Am J Physiol. 1998 Feb;274(2 Pt 2):R294-302.

PMID:
9486284
22.

Novel terphenyls as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents.

Li JJ, Norton MB, Reinhard EJ, Anderson GD, Gregory SA, Isakson PC, Koboldt CM, Masferrer JL, Perkins WE, Seibert K, Zhang Y, Zweifel BS, Reitz DB.

J Med Chem. 1996 Apr 26;39(9):1846-56.

PMID:
8627608
23.

The Role of Cyclooxygenase-2 in Inflammation.

Masferrer JL, Zweifel BS, Colburn SM, Ornberg RL, Salvemini D, Isakson P, Seibert K.

Am J Ther. 1995 Sep;2(9):607-610.

PMID:
11854834
24.

Dual inhibition of nitric oxide and prostaglandin production contributes to the antiinflammatory properties of nitric oxide synthase inhibitors.

Salvemini D, Manning PT, Zweifel BS, Seibert K, Connor J, Currie MG, Needleman P, Masferrer JL.

J Clin Invest. 1995 Jul;96(1):301-8.

25.

In vivo glucocorticoids regulate cyclooxygenase-2 but not cyclooxygenase-1 in peritoneal macrophages.

Masferrer JL, Reddy ST, Zweifel BS, Seibert K, Needleman P, Gilbert RS, Herschman HR.

J Pharmacol Exp Ther. 1994 Sep;270(3):1340-4.

PMID:
7932188
26.

Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.

Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC, Seibert K.

Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3228-32.

27.
28.

Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice.

Masferrer JL, Zweifel BS, Seibert K, Needleman P.

J Clin Invest. 1990 Oct;86(4):1375-9.

29.

Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits.

Daugherty A, Zweifel BS, Schonfeld G.

Br J Pharmacol. 1989 Oct;98(2):612-8.

30.

Isolation of low density lipoprotein from atherosclerotic vascular tissue of Watanabe heritable hyperlipidemic rabbits.

Daugherty A, Zweifel BS, Sobel BE, Schonfeld G.

Arteriosclerosis. 1988 Nov-Dec;8(6):768-77.

PMID:
3196220

Supplemental Content

Loading ...
Support Center